Low Dose Epcoritamab Plus GemOx in R/R DLBCL

Summary

In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.

Eligibility

Inclusion Criteria:

* Subjects with relapsed/refractory diffuse large B-cell lymphoma who have received at least 1 previous line of treatment and that are candidates to autologous stem cell transplant
* ECOG 0-2
* Women of reproductive age who agree on getting a contraceptive method
* Subjects who fulfill Lugano´s criteria for disease activity
* Subjects who voluntarily accept to participate in this study

Exclusion Criteria:

* Active bacterial, viral or fungal infection
* Subjects who have already received an autologous o allogeneic stem cell transplantation
* Subjects with other active neoplasias
* Subjects with end-stage failure

Conditions2

Interventions3

Related trials

• Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL — Australasian Leukaemia and Lymphoma Group
• MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma — Peter MacCallum Cancer Centre, Australia
• Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy — University of Birmingham
• Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma — Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
• A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma — Genmab
• Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma — City of Hope Medical Center
• Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial — City of Hope Medical Center
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma — Genmab

Browse More Trials